Single Pill Cures Deadly Sleeping Sickness in One Day

For generations, sleeping sickness killed Africans by the thousands, and the cure was almost as terrifying as the disease itself: arsenic injections that could prove fatal.

Now, health workers can diagnose and cure the deadly parasitic infection in a single visit with just three tablets. The World Health Organization approved acoziborole on February 27, marking a turning point in the fight against human African trypanosomiasis, a disease spread by tsetse flies that is fatal without treatment.

The numbers tell the story of both crisis and hope. In 1998, sleeping sickness infected an estimated 340,000 people across Africa, with 40,000 confirmed cases and countless others never reached by medical care. Today, that number has dropped dramatically, and this new treatment could drive it to zero.

The old treatments required patients to visit health facilities twice: once for diagnosis, once for treatment days or weeks later. In remote African villages with poor roads and no hospitals nearby, that second visit often never happened. Previous medications demanded multiple doses, intravenous infusions, hospitalization, and a painful spinal tap to determine disease stage.

Acoziborole changes everything. Health workers can now test someone in their village and hand them three pills on the spot. The treatment works for both early and late stage disease, eliminating the need for that dreaded lumbar puncture. No cold storage required. No trained injectors needed. No hospital stay.

The drug builds on more than 20 years of research. Clinical trials in the Democratic Republic of Congo and Guinea proved it works safely and effectively in adults. A pediatric trial called ACOZI-KIDS is now underway to extend approval to children aged one to 14, the only group not yet covered.

Why This Inspires

Dr. Jean-Mathieu Bart works with Guinea's National Programme for the Control of Neglected Tropical Diseases. His country eliminated sleeping sickness as a public health problem last year. "We have seen that it is a very safe and effective drug," he told researchers. "It is obvious that acoziborole will help us accelerate the elimination of transmission by 2030."

The Democratic Republic of Congo, which accounts for two thirds of all sleeping sickness cases in sub-Saharan Africa, represents the critical testing ground. Success there means the drug works where it matters most.

Researchers emphasize that the pill alone won't end sleeping sickness. Communities still need education, vector control to reduce tsetse fly populations, and continued surveillance. But acoziborole removes the biggest barrier between sick people and survival: access to treatment.

A disease that terrorized Africa for centuries can now be cured in one day with medicine that fits in your pocket.